

Supplementary Materials

Table S1. NiV proteins (adapted from source: Uniprot, accessed on March 8, 2023).

Protein Names	Gene Names	Length (Amino Acids)
RNA-directed RNA polymerase L (Protein L)	L	2244
Non-structural protein V	P/V/C	456
Glycoprotein G	G	602
Fusion glycoprotein F0 (Protein F)	F	546
Matrix protein (Protein M)	M	352
Phosphoprotein (Protein P)	P/V/C	709
Nucleoprotein (Protein N) (Nucleocapsid protein)	N	532
Protein W	P/V/C	450

Table S2. HeV Proteins (adapted from source: Uniprot, accessed on March 13, 2023).

Protein Names	Gene Names	Length (Amino Acids)
Fusion glycoprotein F0 (Protein F)	F	546
RNA-directed RNA polymerase L (Protein L)	L	2244
Non-structural protein V	P/V/C	457
Phosphoprotein (Protein P)	P/V/C	707
Nucleoprotein (Protein N) (Nucleocapsid protein)	N	532
Matrix protein (Protein M)	M	352
Glycoprotein G	G	604
Protein C	P/V/C	166
Protein W	P/V/C	448

Table S3. Current Clinical Trials (Source: www.clinicaltrials.gov, accessed on March 10, 2023).

NCT ID	Title	Locations
NCT04199169	Safety and immunogenicity of a Nipah virus vaccine	OH, USA
NCT05178901	Phase 1: evaluate safety and immunogenicity PHV02	KS, USA
NCT05398796	Dose-escalation evaluation of the safety and immunogenicity of mRNA-1215	NIH, MD, USA
NCT01811784	Community intervention to prevent Nipah spillover	Bangladesh